WCN26-8163 Impact of renin-angiotensin system inhibitors discontinuation in advanced chronic kidney disease: a target trial emulation

Read full text Summarise with VIRAT
Authors: Bénédicte Sautenet, Valentin Maisons, Margaux Costes-Albrespic, Sophie Liabeuf, Solène M. Laville, Ziad A. Massy, Angelo Karaboyas, Roberto Pecoits‐Filho, Jean‐Michel Halimi, Étienne Dantan, Natalia Alencar de Pinho
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Renin-angiotensin system (RAS) inhibitors are a cornerstone of the treatment strategy aiming at reducing kidney and cardiovascular risks in patients with chronic kidney disease (CKD). However, it is common practice to stop RAS inhibitors in advanced CKD stages, as an attempt to avoid drug-related adverse effects and/or to delay initiation of kidney replacement therapy (KRT).

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Renin-Angiotensin System Studies Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104274–104274
Publication date
25 March 2026
Language
EN